Premium
KRAS testing on colo‐rectal carcinoma cytological imprints
Author(s) -
Malapelle Umberto,
Bellevicine Claudio,
Russo Anna,
Salatiello Maria,
Palombini Lucio,
Troncone Giancarlo
Publication year - 2011
Publication title -
diagnostic cytopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.417
H-Index - 65
eISSN - 1097-0339
pISSN - 8755-1039
DOI - 10.1002/dc.21417
Subject(s) - kras , medicine , concordance , colorectal cancer , cytology , pathology , panitumumab , carcinoma , cancer
Anti‐EGFR monoclonal antibodies, cetuximab, and panitumumab, are administrated under the condition that advanced colo‐rectal cancer (CRC) carries a wild‐type KRAS gene. Thus, clinicians request pathologists to genotype KRAS before treatment. In the near future routine mutation testing at the same time of the surgery may be implemented. The reliability of a rapid KRAS testing on ex vivo cytological samples obtained by direct scraping of the colon tumour tissue is here evaluated. A consecutive series of 20 surgically resected, primary CRC specimens was analysed. Fresh tissue from CRC was scraped with a scalpel blade, smeared on uncoated glass slides, air‐dried and Diff–Quik stained to ensure malignant cell presence. The same tissue area was also histologically processed. Exon 2 KRAS gene mutations were evaluated on both cytological and histological specimens by dideoxy sequencing and by the DxS KRAS Mutation Test Kit (DxS, Manchester, England). Data obtained on on imprint cytology and matched histological samples showed full concordance; however, the mutation frequency was slightly higher (35%) by the DxS KRAS Mutation Test Kit than by the dideoxy sequencing (30%). Thus, colon cancer imprint cytology sample is a reliable biospecimen for both dideoxy‐sequencing and DxS KRAS Mutation Test Kit analysis and it may be useful to abbreviate the KRAS assay turnaround time. Diagn. Cytopathol. 2011;39:274–277. ©2010 Wiley‐Liss, Inc.